Aclaris Therapeutics, Inc. - Common Stock (ACRS)

Historical Holders from Q4 2015 to Q3 2025

Symbol
ACRS on Nasdaq
CUSIP
00461U105
Type / Class
Equity / Common Stock
Shares outstanding
108M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
91.9M
Holdings value
$130M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
96
Number of buys
51
Number of sells
-64
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock (ACRS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 13.3% $21.8M 14.3M BML Investment Partners, L.P. Dec 31, 2024
Adage Capital Management, L.P. 7.6% -15.6% $12.5M -$2.18M 8.2M -14.8% Adage Capital Management, L.P. Mar 31, 2025
VANGUARD GROUP INC 6.15% +31% $10.2M $2.59M 6.66M +34% The Vanguard Group Jun 30, 2025
BlackRock, Inc. 5.1% $8.37M 5.47M BlackRock, Inc. Jun 30, 2025
Rock Springs Capital Management LP 4.7% $7.72M 5.05M Rock Springs Capital Management LP Mar 31, 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5.87M -$2.61M 3.84M -30.8% Millennium Management LLC Jun 30, 2025

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 155K $294K -$57.1K $1.90 1
2025 Q2 91.9M $130M -$2.09M $1.42 96
2025 Q1 92.2M $141M +$2.11M $1.53 106
2024 Q4 87.5M $217M +$93.7M $2.48 97
2024 Q3 50.9M $58.5M -$1.74M $1.15 76
2024 Q2 52.8M $58.1M -$1.61M $1.10 92
2024 Q1 54.4M $67.4M -$3.19M $1.24 92
2023 Q4 18.2K $19.1K -$176K $1.05 1
2023 Q3 70.1M $480M -$28.1M $6.85 136
2023 Q2 71M $736M +$5.84M $10.37 131
2023 Q1 71.6M $579M +$19.7M $8.09 148
2022 Q4 65.8M $1.04B -$2.52M $15.75 125
2022 Q3 63.6M $1B +$4.19M $15.74 122
2022 Q2 63.2M $883M +$55.6M $13.96 109
2022 Q1 59.1M $1.02B +$65.5M $17.24 105
2021 Q4 55.9M $813M -$38.6M $14.54 129
2021 Q3 56.8M $1.02B +$15.1M $18.00 125
2021 Q2 56M $983M +$174M $17.56 127
2021 Q1 45.4M $1.14B +$405M $25.20 95
2020 Q4 30.4M $197M +$26.7M $6.47 77
2020 Q3 24.3M $62.3M -$3.89M $2.57 50
2020 Q2 28.5M $46.1M -$5.4M $1.62 54
2020 Q1 28.8M $29.9M +$5.25M $1.04 58
2019 Q4 28.1M $53.1M +$4M $1.89 69
2019 Q3 25.9M $28M -$18.8M $1.08 68
2019 Q2 32.6M $71.3M -$14.4M $2.19 78
2019 Q1 37.4M $224M -$10.8M $5.99 87
2018 Q4 38.9M $287M +$36.7M $7.39 91
2018 Q3 29.1M $422M -$34.4M $14.52 77
2018 Q2 31M $619M +$11.6M $19.97 90
2018 Q1 30.2M $528M +$32.3M $17.52 96
2017 Q4 28.5M $702M -$5.46M $24.66 99
2017 Q3 28.5M $735M +$71.5M $25.81 102
2017 Q2 25.6M $694M +$24M $27.12 101
2017 Q1 23.6M $703M +$73.9M $29.82 109
2016 Q4 21.2M $577M +$94.9M $27.14 99
2016 Q3 15.5M $396M +$5.2M $25.61 59
2016 Q2 15.4M $283M +$12.2M $18.47 47
2016 Q1 14.6M $277M +$2.03M $18.95 33
2015 Q4 10.3M $277M +$208M $26.94 31